SCHEMBL8817564

SCHEMBL8817564

COc1cc(-c2nc3c(Cc4ccccc4Br)cc(OCCN4CCCCC4)cc3[nH]2)cc(OC)c1OC

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 6/20 0.44
▸ PARP1 P09874 3/20 0.42
▸ DHODH Q02127 2/20 0.42
▸ TBK1 Q9UHD2 3/20 0.41
▸ IKBKE Q14164 1/20 0.41
▸ ADORA2A P29274 3/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ IL17A Q16552 1/20 0.40
▸ CHEK2 O96017 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8079672 0.89 ACHE (0.46) ACHEPARP1DHODHTBK1ADORA2A
SCHEMBL8079505 0.89 ACHE (0.46) ACHEPARP1DHODHTBK1ADORA2A
SCHEMBL8078747 0.88 LTA4H (0.47) ACHEPARP1DHODHBRD4IL17A
SCHEMBL8891808 0.88 ACHE (0.43) ACHEPARP1DHODHTBK1ADORA2A
SCHEMBL8891268 0.88 ACHE (0.43) ACHEPARP1DHODHTBK1ADORA2A
SCHEMBL8892025 0.87 ACHE (0.42) ACHEPARP1DHODHADORA2ABRD4
SCHEMBL8816596 0.85 ACHE (0.48) ACHEPARP1DHODHTBK1IKBKE
SCHEMBL8071362 0.85 DHODH (0.47) ACHEPARP1DHODH
SCHEMBL8084233 0.84 DHODH (0.42) ACHEPARP1DHODHCHEK2
SCHEMBL8818631 0.84 ACHE (0.42) ACHEPARP1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997033873-A1 METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS ELI LILLY AND COMPANY (US) 1997-09-18 — — WO disclosed
WO-1997031635-A1 METHODS OF TREATING OR PREVENTING SLEEP APNEA ELI LILLY AND COMPANY (US) 1997-09-04 — — WO disclosed
Send feedback